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Abstract. 
Human group IIA secreted phospholipase A2 (sPLA2-IIA) has been characterized in numerous 
inflammatory and neoplastic conditions. sPLA2-IIA can either promote or inhibit cell growth 
depending on the cellular type and the specific injury. We have previously demonstrated that 
exogenous sPLA2-IIA, by engagement to a membrane structure, induces proliferation and 
activation of MAPKs cascade in human astrocytoma cells. In this study we used human 
astrocytoma 1321N1 cells to investigate the key molecules mediating sPLA2-IIA-induced cell 
proliferation. We found that sPLA2-IIA promoted ROS accumulation, which was abrogated in the 
presence of allopurinol and DPI, but not by rotenone, discarding mitochondria as a ROS source. 
In addition, sPLA2-IIA triggered Ras and Raf-1 activation, with kinetics that paralleled ERK 
phosphorylation, and co-immunoprecipitation assays indicated an association between Ras, Raf-1 
and ERK. Additionally, Akt, p70S6K, and S6 were also phosphorylated upon sPLA2-IIA 
treatment, effect that was abrogated by NAC or LY294002 treatment indicating that ROS and 
PI3K are upstream signaling regulators. Since the inhibitors NAC, PD98059, LY294002 or 
rapamycin blocked sPLA2-IIA-induced proliferation without activation of the apoptotic program, 
we suggest that inhibition of these intracellular signal transduction elements may represent a 
mechanism of growth arrest. Our results reveal new potential targets for therapeutic intervention 
in neuroinflammatory disorders and brain cancer in particular. 
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Introduction.  
Human group IIA secreted phospholipase A2 (sPLA2-IIA) belongs to a highly conserved family 
of enzymes with lipolytic activity (Kramer et al., 1989). It is secreted from mammalian cells, 
being its expression regulated by proinflammatory cytokines and growth factors. Primarily 
known for its role in acute and chronic inflammatory diseases such as atherosclerosis (Webb 
2005; Menschikowski et al. 2006), it has also become evident its role in the pathogenesis of CNS 
injuries and certain neurological disorders (Sun et al. 2004; Adibhatla and Hatcher 2007). In 
addition, the recognition that it is overexpressed in numerous tumoral tissues has formed the basis 
of the sPLA2-IIA pro-oncogenic activity concept (Abe et al. 1997; Menschikowski et al. 2008). 
So far, this increased sPLA2 presence in tumor tissues has even opened new therapeutical 
approaches (Jensen et al. 2004). Nevertheless, while many studies have associated the increased 
protein levels of the enzyme with the severity of the diseases, its precise function in 
tumorigenesis remains unclear, having been related either to malignant potential (Dong et al. 
2002; Belinski et al. 2006; Menschikowski et al. 2008) or to reduced tendency towards 
metastasis and longer postoperative survival of patients (Leung et al. 2002).  
Accumulating evidence indicates that secreted PLA2s and specially sPLA2-IIA, in addition to its 
esterase activity, may also exert its biological effects by interacting with different membrane 
targets (Lambeau and Lazdunski 1999; Krizaj and Gubensek 2000; Boilard et al. 2003; Saegusa 
et al. 2008) and behave as cytokine-like molecules.  Thus, different studies mainly performed on 
inflammatory and hematopoietic lineage cells with either bee venom or mammalian secreted 
PLA2s have identified several signaling pathways regulated by the phospholipases such as protein 
kinase C, MEK/ERK1/2, p38 MAPK and PI3-K/Akt cascades, where their capacity to generate 
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biologically active lipids is not required. (Silliman et al. 2002; Triggliani et al. 2002, 2003; 
Gambero et al. 2004). 
However, although sPLA2-IIA acting extracellularly has emerged as an important regulator of 
survival and growth on astrocytoma cells (Hernandez et al. 1998), to our knowledge little 
research has been conducted to examine mechanisticaly their functional role in neoplastic 
disorders of the CNS. 
In 1321N1 human astrocytoma cells, we have previously described the existence of a signaling 
pathway triggered by exogenous sPLA2, that induces phospholipase C-1 activation and Ca2+ 
mobilization and modulates the MAPK cascade resulting in a mitogenic response (Hernández et 
al. 1998, 1999). To obtain further insight into the aforementioned signaling effects, we 
considered the fact that reactive oxygen species (ROS), prototypical molecules associated with a 
variety of diseases such as cancer or ischemia, may contribute to increase growth and DNA 
synthesis, and that mitogen-activated protein kinases (ERK/MAPK), as well as the 
serine/threonine protein kinase Akt are key mediators of ROS-induced growth in response to 
different stimuli (Chen et al., 1995; Wang et al. 2000). Therefore, we addressed the actions of 
exogenous sPLA2-IIA on ROS buildup, as well as on activation of key molecules of the 
proliferative networks: Ras/Raf-1/MEK/ERK and PI3K/Akt/mTOR. 
Hence, this research greatly increases the knowledge of the intracellular networks by which 
secreted phospholipases, especially sPLA2-IIA, may functionally modulate the evolution of CNS 
tumors, improving the understanding, not only of the underlying molecular biology of astrocytic 
tumor cells, but also of the signaling mechanisms modulated by sPLA2-IIA. 
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Materials and Methods. 
Materials. See Supplementary Material online for details 
Cell culture and transfection. 1321N1 human astrocytoma cells were grown in DMEM 
supplemented with 5% FCS, 100 U/ml penicillin and 100 g/ml streptomycin in a 37°C incubator 
with 5 % CO2. Cells were transfected by the calcium-phosphate method with pMT2-HA-Ras or 
empty vector expressed in E. coli DH5alpha cells and purified with a Qiagen maxiprep kit 
following the manufacturer’s instructions. 
ROS production and mitochondrial inner transmembrane potential detection. 
Measurements of superoxide-derived ROS accumulation in DCFH-DA-preloaded cells in 
response to 1 g/ml of sPLA2-IIA were carried out as previously described (Martin et al., 2007). 
In some experiments, cells were treated for 30 min with the indicated antioxidant before 
incubation with the phospholipase. 
To evaluate mitochondrial transmembrane potencial (m), cells were treated with 1 g/ml of 
sPLA2-IIA for 6 or 18 h. and then 1 M rhodamine 123 was added to the culture. Cells were 
analysed immediately by flow cytometry. 
Cell proliferation. Cell proliferation was evaluated by a [3H]-thymidine incorporation assay. 
Cells were starved for 24 h and then treated with 1 g/ml of sPLA2-IIA in the presence or 
absence of the indicated inhibitors. After 24 h of incubation, cells were labeled with 0.5 Ci [3H]-
thymidine/ml during 4 additional hours, and incorporation was assessed by scintillation counting. 
Values were normalized by setting sPLA2-IIA-stimulated cells to 100%. Numerical data are mean 
± SD of 4 different experiments, each performed in triplicate. 
Trypan blue dye assay. See Supplementary Material online for details. 
Analysis of apoptosis. After a 24 h treatment with 1 g/ml of sPLA2-IIA in the presence or 
absence of the indicated inhibitors, cells were visualized and photographed with a 40× objective 
in a Nikon Eclipse 80i microscope, or used for an Annexin V-PE Apoptosis Detection Assay. 
Briefly, cells were resuspended in binding buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 2.5 
mM CaCl2, 1 mM MgCl2, 4% BSA), and incubated for 30 min with Annexin V-PE, followed by 
flow cytometric analysis using an EPICS XL cytofluorometer, Beckman-Coulter.  
Analysis of endogenous Ras activation. Ras activation was determined using bacterially 
produced GST–Raf-RBD (kindly provided by Dr. J.L. Bos). After stimulation, cells were lysed 
on ice in lysis buffer (15% glycerol, 50 mM Tris-pH 7.4, 1% NP-40, 200 mM NaCl, 5 mM 
MgCl2, 1 mM phenylmethylsulfonyl fluoride, 1µM leupeptin, 0.1M aprotinin). Cellular debris 
was removed and supernatants were incubated for 30 min at 4 °C with GST–Raf-RBD (15 
g/sample) coupled to glutathione–Sepharose beads (10 l/sample). The precipitated complexes 
were boiled in SDS sample buffer. Total lysates and precipitates were analysed by Western Blot 
using an antibody against Ras.  
Immunoblotting and Immunoprecipitation. This is described in the Supplemental Material. 
Data Presentation Each set of experiments was repeated at least three times. Unless otherwise 
indicated, the data presented are from representative experiments. Numerical data are expressed 
as means + SD and analyzed with the SPSS software for statistical significance using Student's t 
test. A p value <0.05 was considered significant.  
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Results 
sPLA2-IIA induces ROS generation in 1321N1 cells. Enhanced ROS levels have been observed 
in cells in response to growth factors or cytokines, and numerous studies suggest their 
participation in cell proliferation. To determine their role in sPLA2-IIA-mediated 1321N1 
astrocytoma cell growth, we first examined the ability of the phospholipase to elicit ROS 
production using the probe DCFH-DA. The results obtained demonstrated that cell exposure to 
sPLA2-IIA led to a remarkable increase in DCF fluorescence in a dose- and time-dependent 
manner compared to control cells.  Figure 1A shows that accumulation of superoxide-derived 
ROS was observed around 5 min after stimulation with 1 g/ml of sPLA2-IIA and rapidly 
increased to its maximum levels around 15-30 min.  Although we detected ROS generation at 0.1 
g/ml (18 %  cells were positive), maximal effect was observed between 1-5 g/ml (47 % cells 
were positive) compared to untreated cells (5 % cells were positive) (Fig. 1B). Hence, in 
subsequent experiments 1 g/ml of sPLA2-IIA was used as optimal concentration for signaling 
studies. We also performed experiments with human recombinant sPLA2-IIA obtained from 
C127 cells stably transfected with the coding sequence of sPLA2-IIA from human placenta with a 
very similar, if not identical results (data not shown).  
Next, we examined the effect of some scavenger enzymes, such as catalase (CAT) or superoxide 
dismutase (SOD), and synthetic antioxidants, such as N-acetylcysteine (NAC), or the radical 
scavenger pyrrolidine dithiocarbamate (PDTC). For this purpose, 1321N1 cells were incubated 
for 30 min with either 50 or 100 U/ml of CAT, 50 or 500 U/ml of SOD, 5 or 10 mM of NAC, or 
50 or 100 M of PDTC prior to the addition of the phospholipase. Under these conditions, all the 
antioxidants notably attenuated sPLA2-IIA-induced ROS upregulation (Fig. 2 A,B).  
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Then, we investigated the source of phospholipase-induced ROS production in 1321N1 cells. We 
used various inhibitors of possible enzymatic sources: DPI (10-20 M) an inhibitor of 
flavoenzymes, such as xanthine oxidase or NADPH oxidase (NOX) isozymes, allopurinol (50-
100 M) a potent xanthine oxidase inhibitor, and rotenone (5-10 M) a mitochondrial complex I 
inhibitor. As shown in Figure 2C, the presence of either 100 M allopurinol or 20 M DPI 
abolished DCF fluorescence of sPLA2-IIA-treated cells, therefore, ROS production. In contrast, 
no concentration of rotenone was able to alter DCF fluorescence, making mitochondrial electron 
transport an improbable ROS source. 
Finally, we evaluated whether this ROS overproduction led to changes in m that would result 
in alteration of mitochondrial function using Rhodamine 123, a specific fluorescent probe, whose 
uptake and retention into the mitochondrial matrix depends on the m. In this study we also 
used a ROS inducer, oleanolic acid (OA), as a positive control for m depolarization (Martín et 
al., 2007) As shown in Figure 2B, sPLA2-IIA did not affect Rhodamine 123 accumulation in 
1321N1 cells after 6 or 18 h of stimulation compared to untreated control cells, while in OA-
treated cells a reduced uptake and retention of the dye was detected. In fact, after 6 or 18 h of 
incubation with 25 M OA, a decrease of 82% and 96% in fluorescence was noted, whereas in 
sPLA2-IIA-treated cells it remained at similar levels to those found in untreated cells.  
Effect of sPLA2-IIA on the classical Akt and ERK signaling pathways. Several studies have 
suggested that Ras plays an important role in a variety of cells through the sequential activation 
of the Raf-1 /MEK1/2/MAPK pathway, and in 1321N1 astrocytoma cells we have already 
demonstrated MAPK activation upon cell exposure to sPLA2-IIA (Hernández et al. 1998). To 
elucidate whether the activation of Ras/Raf were also signaling elements of the phospholipase 
action, cells were incubated in the absence or presence of an optimal concentration of sPLA2-IIA 
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(1 g/ml) for different times. As it can be seen in Figure 3A, sPLA2-IIA treatment increased Ras-
GTP formation in a time dependent manner, reaching the maximum level around 5 min. At 
similar time points, Raf-1 phosphorylation and translocation to the plasma membrane was also 
assessed. Figure 3B shows that both kinetics of Raf phosphorylation and translocation correlated 
with that of Ras activation (Fig.3 A,B) and also paralleled the ERK activation/phosphorylation 
profile (data not shown) (Hernandez et al. 1998), supporting a relationship between 
Ras/Raf/ERK. To get an insight into this process, cells were subjected to an immunoprecipitation 
assay with an anti-Raf-1 antibody. Figure 3C shows the results of a representative experiment in 
which the association of Raf with Ras and ERK was examined in immunoprecipitates from cells 
exposed to sPLA2-IIA. We found that 1 g/ml of sPLA2-IIA pulled together Ras, ERK and Raf-1. 
In addition, 1321N1 cells were transfected with HA-Ras or empty vector, treated with sPLA2-
IIA, and then total cell extracts were subjected to an immunoprecipitation assay with an anti-HA 
antibody. As shown in Figure 3D, sPLA2-IIA induced Ras association with p-Raf-1 and p-ERK.  
 
Next, considering that Akt is another key signal-transduction enzyme that has been implicated in 
the promotion of cell survival as well as growth (Cantley 2002), we investigated whether sPLA2-
IIA affected Akt activity on astrocytoma cells. To address this question, we examined the Akt 
phosphorylation status at Thr308 and Ser473 upon exposure of 1321N1 cells to sPLA2-IIA, since 
phosphorylation at both residues is required for its full activation. As shown in Figure 4A, we 
observed a significant and sustained increase in Akt phosphorylation on both residues in the 
presence of sPLA2-IIA. The phosphatidylinositol 3 kinase (PI3K) inhibitor, LY294002, abrogated 
the phosphorylation of Akt at both sites -in order to simplify the figure, we only show the western 
blot for Ser 473, phosphorylation, required to get maximum activation of Akt-, suggesting that 
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PI3K is an upstream mediator of Akt activation in 1321N1 astrocytoma cells. However, this 
inhibitor did not affect sPLA2-IIA-induced ERK phosphorylation. 
To further characterize the relationship between ERK and PI3K signaling pathways, we also 
evaluated the effect of the MEK inhibitor, PD98059, on Akt phosphorylation. We observed that 
pre-treatment of 1321N1 cells with PD98059 had no significant effect on phospholipase-induced 
Akt phosphorylation (both at Thr308, fig 4A, and Ser473, not shown), indicating that both kinases 
can be activated independently in separate signaling pathways. 
Next, we studied downstream Akt targets in the context of cell proliferation. In particular, we 
focused on the rapamycin-sensitive molecules p70 ribosomal protein S6 kinase (p70S6K) and S6 
ribosomal protein (S6). We found that upon sPLA2-IIA treatment, both proteins were persistently 
phosphorylated in 1321N1 cells, with a maximal effect reached at 30 min that was sustained for 
at least 240 min (Fig 4B). In untreated samples, a low level of phosphorylated S6 protein was also 
detected and its functional significance needs to be determined. Then, we evaluated the effects of 
the PI3K inhibitor, LY294002, and the mammalian target of rapamycin (mTOR) inhibitor, 
rapamycin (RAP), on p70S6K and S6 phosphorylation. We found that the presence of these 
compounds considerably decreased the phosphorylation of both proteins (Fig. 4B).  
Interestingly, the presence of the MEK inhibitor, although ineffective in blocking Akt 
phosphorylation, it significantly reduced p70S6K and S6 phosphorylation induced upon sPLA2-
IIA treatment (Fig 4C). 
 
In addition, to establish the selectivity and specificity of the sPLA2-IIA on the aforementioned 
effects, we first investigated the signaling capabilities of the human recombinant sPLA2-IIA, as 
well as of the other sPLA2. As shown in Figure S1A, astrocyte stimulation with 1 g/ml of 
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human recombinant-sPLA2-IIA, sPLA2-IB or sPLA2-IIIA, also resulted in ERK and Akt 
phosphorylation while not major effects were observed with sPLA2-V. Next, to determine 
whether the catalytic activity affects the ability of sPLA2-IIA to induce these cytokine-like 
responses, the actions of the phospholipase were evaluated in the presence of EGTA (calcium is 
mandatory for its catalytic activity) or oleanolic acid (pharmacological inhibitor IC50: 3-7M) 
(Dharmappa et al. 2009), and using sPLA2-IIA irreversibly inactivated with BPB (Hernandez et 
al. 1998). Figure S1B shows that in none of those conditions, where the catalytic activity of the 
phospholipase is compromised, its ability to promote ERK and Akt phosphorylation is affected. 
Taken together, those results indicate that the cellular responses induced by the sPLA2-IIA are 
independent of its enzymatic activity, and can be reproduced by other isoforms.  
Effect of ROS on sPLA2-IIA downstream signaling in 1321N1 cells. ROS production, 
similarly to second messengers, has been suggested to indirectly affect signal transduction 
processes. To determine whether ROS could serve as mediators of sPLA2-IIA downstream 
signaling, we assessed the effect of disrupting ROS generation on Ras activation and on ERK, 
cPLA2 and Akt phosphorylation. Phosphorylated cPLA2 was detected by the retardation of its 
electrophoretic mobility (gel-shift), while phosphorylated ERK, Akt and p70S6K were analysed 
using phospho-specific antibodies. As shown in Figure 5A and B, NAC, a general ROS 
scavenger, was neither effective in blocking sPLA2-IIA-induced Ras-GTP, nor in abrogating the 
phosphorylation of its downstream signaling molecules, ERK or cPLA2. Another ROS scavenger, 
PDTC, did not show either an effect. However, sPLA2-IIA-induced Akt/p70S6K phosphorylation 
was significantly attenuated at all three NAC doses tested (Fig. 5C). 
sPLA2-IIA-induced 1321N1 cell proliferation requires ROS induction and activation of 
ERK and PI3K/mTOR pathways. Consistent with previously reported data, exposure of 
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1321N1 cells to sPLA2-IIA caused a significant increase in DNA synthesis (Hernández et al. 
1998). Thus, within 24 h of treatment, 1321N1 cells increased [3H]-thymidine incorporation up to 
34,470 ± 2,299, from 5,430 ± 1,680 in control cells. To investigate the signaling pathways that 
might be involved in this proliferative response, [3H]-thymidine incorporation was measured in 
the presence of inhibitors acting at different levels of the cascades regulated by sPLA2-IIA. We 
found that NAC, PD98059, LY294002 or rapamycin, were all effective preventing the 
stimulatory effect of the phospholipase on cell growth (n = 3; p < 0.05) (Fig. 6A) In parallel, cell 
viability was determined by the Trypan blue dye exclusion assay. As shown in Figure 6B, we 
found no major differences in the proportion of Trypan blue-positive cells at any experimental 
condition, suggesting that the population of dead cells is not increased under these culture 
settings in which the proliferation is blocked. In addition, microscopic observations of the cells, 
using a phase-contrast microscope revealed that these treatments did not affect either cellular 
appearance or attachment (Fig. 6C). 
Finally, to explore whether apoptosis was involved in this inhibitory effect, we analysed 
phosphatidylserine externalization (an early event in apoptosis) by an annexin-V staining assay. 
As shown in Figure 6 D, flow cytometry analysis showed no annexin V-positive cells upon 
sPLA2-IIA treatment, neither in the presence, nor in the absence of the different inhibitors, 
meaning no phosphatdylserine exposure on the outer membrane of the cells.  
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Discussion 
Tumor progression frequently depends on interactions between tumoral cells and molecules 
present in its microenvironment, the “seed and soil” hypothesis developed by Paget (Paget et al. 
1889). Microenvironmental factors influence the biological behaviour of tumor cells and, in 
many cases the same molecule operating under different circumstances may exert opposing 
effects, acting as a doubledged sword. In searching for such regulatory agents, sPLA2-IIA surges 
as a multifunctional protein playing promalignancy and antimalignancy roles in tumor 
progression depending on the cell type and context (Dong et al. 2002; Belinski et al. 2006; 
Menschikowski et al. 2008; Leung et al. 2002). In this study, we show that sPLA2-IIA mediates 
astroglial tumor cell growth and involves the activation of the major intracellular signaling 
cascades: Ras/MEK/ERK and PI3K/AKT/mTOR pathways. To our knowledge, this is the first 
report to demonstrate that exogenous sPLA2-IIA promotes ROS accumulation in brain tumor 
cells and that the activated PI3K/AKT/mTOR signaling pathway is ROS sensitive. Our data also 
suggest that both cascades converge to regulate cellular growth, since the inhibition of any of 
those pathways prevents sPLA2-IIA proliferative effect without affecting cell survival. 
Involvement of these molecules in cell survival, growth, as well as in malignant transformation, 
in response to extracellular signals has been previously established in different cellular types. 
However, the relationship between these intracellular mediators and the mechanisms of action of 
human sPLA2-IIA on brain tumor cells remained to be determined, since, besides activation of 
MAPKs, arachidonate metabolism or Ca2+ mobilization (Hernández et al. 1998), little is known 
about the pathways activated by this particular phospholipase isoform. 
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Group IIA secreted phospholipase A2 is an acute phase protein that has been characterized in 
different pathological processes, being its presence usually linked to inflammatory disorders (Abe 
et al. 1997; Webb 2005).  
It has been shown that sPLA2-IIA induces an apoptotic response restricted to neurons (Yagami et 
al. 2002), being recently found that in cerebellar neural cells the mitochondrial sPLA2 mediates 
apoptotic activities through ROS generation (Mathisen et al. 2007). However, in non-neuronal 
cells, including astrocytes, it triggers survival, differentiation or even proliferative signals 
(Fonteh et al. 2001; Yagami et al. 2002; Saegusa et al. 2008), remaining the precise molecular 
mechanism involved an enigma. Thus, although the contribution of sPLA2-IIA, as well as the 
other sPLA2 isozymes, to these degenerative disorders is increasingly relevant, clear information 
about their functions is not available yet.  
In this study we have made use of the well characterized 1321N1 astrocytoma cells, where 
sPLA2-IIA acts as a mitogen to go further inside its mechanisms of action. The first finding of 
this paper is that 1321N1 cells are prone to generate ROS upon phospholipase stimulation. NOX 
isozymes, and possibly, xanthine oxidase contribute to this response, probably acting 
synergistically, as previously described (Isabelle et al. 2007), since both DPI and allopurinol 
were effective drugs blocking ROS levels. In contrast, the presence of rotenone, an inhibitor of 
complex I of the mitochondrial respiratory chain, did not affect intracellular ROS; therefore we 
can assume that mitochondria are not a probable source of ROS in this context. In addition, we 
neither observed that rotenone promotes cellular ROS accumulation, results in conflict with 
previously reported studies that show that rotenone triggers mitochondrial ROS induction (Li N 
et al. 2003). This discrepancy may be due to a different antioxidant capacity of the cellular 
systems used. In fact MnSOD, a primary mitochondrial antioxidant, is strongly expressed in glial 
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tumors and, in agreement with the above mentioned study, when MnSOD is overexpresed, 
rotenone-induced increase of cellular ROS is inhibited. 
Besides, m was not either disrupted upon sPLA2-IIA treatment, discarding also mitochondria 
as a ROS target. Moreover, we have observed that sPLA2-IIA-induced ROS generation is 
involved in growth rather than in apoptosis, since the presence of NAC abrogated the 
proliferative response. The fact that both catalase and SOD were effective blocking ROS 
accumulation, suggests a reaction route starting with the sPLA2-IIA-mediated reduction of 
molecular oxygen to superoxide, followed by spontaneous dismutation to H2O2. 
Mechanistically, ROS have been linked to tyrosine kinases, ERK and Akt signaling to regulate 
diverse biological functions, including survival and growth (Chen et al., 1995; Wang et al. 2000). 
It is well established that ERK is a component of the Ras signal transduction pathway and a 
considerable number of data consider this cascade as one of the primordial signaling network that 
governs cell survival, growth or differentiation. Previous studies have shown that Ras is crucial 
for thrombin-induced mitogenesis in 1321N1 cells (LaMorte et al. 1993). Therefore, our earlier 
results showing ERK activation in 1321N1 cells upon exposure to sPLA2-IIA led us to 
characterize the activation of classical upstream effectors: Ras and Raf-1. However, although this 
cascade could be activated by ROS, here we show that treatment of 1321N1 cells with ROS 
scavengers does not affect the sPLA2-IIA-activated Ras/Raf/ERK network, suggesting a ROS-
independent regulation. On the other hand, the Ras/ERK cascade itself might be involved in the 
generation of high ROS levels (Serù et al., 2004); however, in our system, the presence of MEK 
inhibitors does not affect ROS production (data not shown), indicating that the ERK cascade is 
not either an upstream signaling system implicated in ROS accumulation. 
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The PI3K/Akt system, another effector of intracellular ROS, classically participates in pathways 
targeting cellular proliferation in both normal and tumoral cells. In particular, a critical role for 
Akt has been ascribed to the survival of astrocytes and glioblastomas in different model systems 
(Sonoda et al. 2001). In fact, current evidence supports the concept that Akt, through a complex 
network with multiple components, such as mTOR, p70S6K or S6, plays an essential role in cell 
growth and protein translation (Fingar et al. 2004). However, the sequential activation of this 
transduction pathway is complex and not completely understood, being probably context-
specific. In this way, it has been shown in cortical neurons, that phosporylation of p70S6K and its 
substrate, S6, can take place in a rapamycine-dependent manner (Ishizuka et al., 2008), or in 
ovarian cancer cells PI3K transmits the mitogenic signal through Akt and mTOR to p70S6K 
(Gao et al., 2004). However, in other systems, the p70S6K/S6 cascade can be activated 
independently of mTOR, being Akt, ERK or even phosphatidic acid, direct upstream effector 
molecules (Riemenschneider et al. 2006; Lehman et al. 2007). 
Here we report that in human 1321N1 cells, sPLA2-IIA elicits a sustained phosphorylation of 
Akt, p70S6K and S6, which is prevented by the presence of the antioxidant NAC and by the 
inhibitor LY294002, suggesting a ROS-dependence, and a role for PI3-kinase in this pathway. In 
addition, we find that inhibition of mTOR signaling with rapamycin abrogates p70S6K/S6 
phosporylation. This demonstrates the induction of an active and functional 
PI3K/Akt/mTOR/p70S6K/S6 redox-sensitive cascade in 1321N1 cells upon exposure to sPLA2-
IIA. These data agree with previously reported studies with either human sPLA2-IIA (on murine 
macrophages), or other sPLA2 isozymes, such as mammalian group IB (on mouse fibroblasts) or 
snake venom group IA (on human lung macrophages), which link sPLA2-biological activity to 
PI3K and Akt activation (Park et al.. 2003; Choi et al. 2004; Granata et al. 2006). In contrast, it 
has been shown that bee venom sPLA2-III treatment induces on renal cancer cells a remarkable 
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inhibition of the Akt activity that prevents the transduction of survival signals (Putz et al. 2007). 
This points to a certain degree of selectivity displayed by distinct sPLA2s, and highlights the need 
to know the cascade of intracellular events regulated by each particular phospholipase.  
In astrocytoma cells, the intracellular signals induced by sPLA2-IIA can be reproduced by other 
isozymes, although not by group V, remaining unknown their functional and mechanistic 
significance. These results underscore the importance of future studies aimed at characterizing 
the biological effects of the different sPLA2s on glioma cells, and the role therein of binding 
versus enzymatic activity, especially for group V because of its demonstrated activity on the 
phosphatidylcholine-rich outer plasma membrane of mammalian cells. In contrast, sPLA2-IIA is 
barely efficient hydrolyzing membrane phospholipids from the outer layer of mammalian cells 
due to its preference for anionic phospholipids, probably grounding the distinct roles of these two 
enzymes. In this way, we have observed that the effects induced by sPLA2-IIA cannot be 
attributed to its enzymatic activity, since the cytokine-like characteristics of sPLA2-IIA are 
maintained in a catalytically inactive environment. Therefore, although the proposed roles of 
sPLA2 enzymes have largely been inferred from their enzymatic properties, their actions through 
interaction with membrane targets should be considered and defined. 
 
Regarding sPLA2-IIA actions, assays using specific kinase inhibitors show that sPLA2-IIA needs 
the simultaneous functional activity of the ERK and Akt/mTOR systems to induce a proliferative 
phenotype in 1321N1 cells. The PI3-kinase inhibitor, LY294002, and the MEK inhibitor, 
PD98059, suppress sPLA2-IIA-induced cell growth. However, LY294002 does not affect ERK 
and PD98059 does not abolish Akt phosphorylation. Therefore, components of these pathways 
are probably converging on factors that regulate proliferation, at a different level than ERK and 
Akt.  
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In this sense, there is molecular evidence that growth factor-activated MAPK and PI3K cascades 
activate RSK and p70S6K proteins, respectively, and converge at the level of eIF4B 
phosphorylation to stimulate translation (Shahbazian et al. 2006). In addition, recent studies have 
shown that pharmacological inhibition of ERK does not affect phosphorylation of Akt, while it 
elicits a reduction of p70S6K activity and prevents S6 and 4E-BP1 phosphorylation to a similar 
extent to that induced with rapamycin, decreasing ribosomal biogenesis and protein translation 
efficiency. Interestingly, in our studies PD98059 pretreatment also blocks the sPLA2-IIA induced 
phosphorylation of p70S6K/S6. This clearly suggests that MEK1/2 is a critical intermediary of 
phospholipase-mediated p70S6K activation, therefore connecting Ras and PI3K pathways. The 
molecular level of interaction between these two signaling pathways should be studied in depth, 
considering the different recent hypothesis: (i) ERK is a direct p70S6K kinase (Iijima et al. 2002) 
(ii) other kinases regulated by MEK are necessary for p70S6K activation or, (iii) the 
tuberin/hamartin complex acts as a signal integrator, where the Ras and PI3K pathways converge 
to modulate growth (Shahbazian et al. 2006). 
It is noteworthy that, although sPLA2-IIA proliferation is abrogated by inhibiting any component 
of the ERK or Akt signaling pathways, survival is not affected. It is accepted that inhibition of 
cellular growth in the absence of apoptosis would commit the cell into a differentiation program 
(Mijatovic et al. 2005); defining whether this machinery is triggered by sPLA2-IIA demands 
further investigation. 
Taken together, our findings put forward that, in 1321N1 cells, sPLA2-IIA acts as an agonist to 
which cells respond by activating ROS-independent Ras/ERK and ROS-dependent Akt/mTOR 
pathways, which converge, ultimately leading to cell proliferation; and where MEK and/or ERK 
play an essential role connecting these two major signaling networks. 
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Figure Legends 
 
FIG. 1.- sPLA2-IIA induces intracellular ROS generation in 1321N1 cells. 1321N1 cells were 
incubated with 1 g/ml sPLA2-IIA for different times (A) or for 30 min with different doses (B). 
ROS levels were measured by flow cytometry analysis after staining with the fluorescent probe 
DCFH-DA. Solid gray curves, cells without treatment (control); empty black curves, sPLA2-IIA-
treated cells. Representative histograms are shown. 
 
FIG. 2.- A, Effect of antioxidants on sPLA2-IIA-induced ROS production. 1321N1 cells were 
incubated without or with 1 g/ml of sPLA2-IIA for 30 min in the presence or absence of the 
indicated antioxidants (A, B, C). ROS levels were measured by flow cytometry analysis after 
staining with the probe DCFH-DA. Solid gray curves, cells in the absence of treatment (control); 
empty black curves, sPLA2-IIA-treated cells; and empty gray curves, sPLA2-IIA-treated cells in 
the presence of antioxidants. D, Effect of sPLA2-IIA on mitochondrial membrane potential. The 
mitochondrial membrane potential was analysed using the dye, rhodamine 123. 1321N1 cells 
were stimulated without or with 1 g/ml of sPLA2-IIA or 25 M of OA for 6 or 18 h, and 
mitochondrial dysfunction was determined by flow cytometry analysis.  
 
FIG. 3.- sPLA2-IIA induces activation of the Ras/Raf/ERK cascade in 1321N1 cells. 1321N1 
cells were incubated with 1g/ml sPLA2-IIA for different times. Protein lysates were utilized for 
a Ras-pulldown assay (A), for Western blotting with a phospho-specific Raf-1 antibody (B, upper 
panel) or for immunodetection of Raf-1 in the membrane fraction (B, lower panel). C, 1321N1 
cells were stimulated for the indicated times with 1 g/ml sPLA2-IIA, subjected to 
immunoprecipitation with anti-Raf-1, and blotted against the specified antibodies. Membranes 
 28
were reprobed with anti-Raf-1 to demonstrate equal loading of protein. D, 1321N1 cells 
transfected with HA-Ras were stimulated for 2 or 5 min with 1 g/ml sPLA2-IIA, subjected to 
immunoprecipitation with an anti-HA antibody, and blotted against anti-p-Raf-1 and anti-p-
ERK1/2 antibodies. The higher molecular weight IgG band was used as reference for equal 
loading of samples. Actin present in the total cell extract also is shown. In addition, equal gel 
loading and membrane transference was confirmed by Ponceau S and Coomassie staining, 
respectively.  These are representative experiments of 4 similar ones.  
 
FIG. 4.- sPLA2-IIA activates Akt and the downstream targets p70S6K and S6 in 1321N1 cells. 
1321N1 cells were incubated without or with 1 g/ml sPLA2-IIA for 15 min in the presence or 
absence of the indicated inhibitors. Lysates were analysed by Western blotting with the specified 
antibodies.  
 
FIG. 5.- Effect of NAC on the intracellular signaling mediators activated in sPLA2-IIA-treated 
cells. 1321N1 cells were incubated without or with 1 g/ml sPLA2-IIA for different times (A) or 
for 15 min (B,C), in the presence or absence of antioxidants. Protein lysates were: (A) utilized for 
Ras-pulldown assay followed by immunoblotting detection with anti-Ras, or (B, C) analysed by 
Western blotting with phospho-specified ERK, Akt or p70S6K antibodies. Prolonged SDS-PAGE 
electrophoresis was used to detect the band-shift characteristic of cPLA2 phosphorylation (B, ii).  
 
FIG. 6.- Effect of different inhibitors on cellular growth and survival in sPLA2-IIA-treated cells. 
1321N1 cells were incubated with 1 g/ml sPLA2-IIA in the presence or absence of different 
doses of antioxidants/inhibitors for 24 h. Cell proliferation was determined with a [3H]-thymidine 
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assay (A), and cell viability by Trypan blue exclusion (B). Values are means ± SD from 4 
experiments. C, Representative phase micrographs of cells treated with control solvents, or the 
indicated inhibitors in the presence of sPLA2-IIA for 24 h. D, Apoptosis was determined by using 
the annexin-V binding assay and flow cytometry analysis. Solid grey curves, cells without any 
treatment (control); empty black curves, sPLA2-IIA-treated cells without antioxidant/inhibitor; 
and empty grey curves, sPLA2-IIA-treated cells in the presence of the antioxidant/inhibitor. 
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